Your shopping cart is currently empty

Thymulin is a peptide hormone which is mainly produced by thymic epithelial cells and it has immune-modulatory and anti-inflammatory effects

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $39 | In Stock | In Stock | |
| 5 mg | $89 | In Stock | In Stock | |
| 10 mg | $135 | In Stock | In Stock | |
| 25 mg | $226 | In Stock | In Stock | |
| 50 mg | $336 | In Stock | In Stock | |
| 100 mg | $490 | In Stock | In Stock | |
| 200 mg | $713 | In Stock | In Stock |
| Description | Thymulin is a peptide hormone which is mainly produced by thymic epithelial cells and it has immune-modulatory and anti-inflammatory effects |
| In vitro | The effects of different doses and various timings of thymulin intraperitoneal administration on spinal microglial activity and intracellular pathways in an inflammatory rat model of Complete Freund's adjuvant (CFA).?Thymulin treatment was implemented following CFA-induced inflammation for 21 days.?After conducting behavioral tests (edema and hyperalgesia), the cellular and molecular aspects were examined to detect the thymulin effect on inflammatory factors and microglial activity.?Demonstrated that thymulin treatment notably reduced thermal hyperalgesia and paw edema induced by CFA.?Furthermore, molecular investigations showed that thymulin reduced CFA-induced activation of microglia cells, phosphorylation of p38 MAPK and the production of spinal pro-inflammatory cytokines (TNF-α, IL-6) during the study.?Results suggest that thymulin treatment attenuates CFA-induced inflammation.?This effect may be mediated by inhibition of spinal microglia and production of central inflammatory mediators which seems to be associated with the ability of thymulin to reduce p38 MAPK phosphorylation.?These data provide evidence of the anti-hyperalgesic effect of thymulin on inflammatory pain and characterize some of the underlying spinal mechanisms[1]. |
| Molecular Weight | 858.85 |
| Formula | C33H54N12O15 |
| Cas No. | 63958-90-7 |
| Smiles | CC(NC(=O)C1CCC(=O)N1)C(=O)NC(CCCCN)C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NCC(=O)NCC(=O)NC(CO)C(=O)NC(CC(N)=O)C(O)=O |
| Relative Density. | 1.417 g/cm3 (Predicted) |
| Sequence | {Pyr}-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn |
| Sequence Short | {Pyr}-AKSQGGSN |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||
| Solubility Information | H2O: 10 mM, Sonication is recommended. DMSO: Insoluble | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
H2O
| |||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.